Turning Point Therapeutics, Inc.
COMBINATION THERAPY INVOLVING DIARYL MACROCYCLIC COMPOUNDS
Last updated:
Abstract:
The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with an inhibitor of MAPK/ERK kinase-1 and -2 (MEK1 and MEK2; MAP2K1 and MAP2K2), such as trametinib.
Status:
Application
Type:
Utility
Filling date:
25 Nov 2020
Issue date:
27 May 2021